Accessibility and reading comfort

Text size

Light/Dark mode

Lines vertical spacing

Trouble using our website?
Contact us

Ghent University Hospital, Ghent, Belgium

In this page

How to contact the center

Full member

HCP Center

The Ghent University Hospital is one of the largest and most specialized hospitals in Flanders with more than 3,000 patients a day and more than 6,000 employees. Patients are offered a wide range of top referent care. The hospital has extensive facilities and more than 1,000 beds for single-day and multi-day inpatient stays.
As a university medical center, Ghent University Hospital also invests in research, education and training and works closely together with the Faculty of Medicine and Health Sciences of Ghent University. The latter offers a wide range of study programmes in medicine and health sciences, as well as the associated research activities. Research at the faculty is very diverse, ranging from fundamental (bio)medical research to translational and clinical academic research. Clinicians and healthcare professionals are continuously trained and researchers including clinician-scientists study many new diagnostic and therapeutic approaches.
More information on www.uzgent.be and www.ugent.be/ge/en

Contact

Ghent University Hospital, Ghent, Belgium

Corneel Heymanslaan 10
9000 Ghent
Belgium

Team

Pr Bart LEROY

Representative

Belgium

Genetic Diagnostics (TWG6), Low Vision Daily Life and Patients Groups (TWG5), National Integration (TWG9), Research (TWG8), Retinal Rare Eye Diseases (WG1)
Working Group Leader
See more

Pr Elfride DE BAERE

Substitute

Belgium

Genetic Diagnostics (TWG6), Retinal Rare Eye Diseases (WG1)
Working Group Leader
See more

Clinical trials

NCT04855045 - Unknown

An Open-Label, Dose Escalation and Double-Masked, Randomized, Controlled Study to Evaluate the Safety and Tolerability of Sepofarsen in Pediatric Subjects G (p.Cys998X) Mutation.

Interventional
See the trial
voir la fiche
NCT05566795 - Recruiting, Active

A Phase 3, Randomized, International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients with Pediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Therapy

Interventional
See the trial
voir la fiche

NCT05063162 - Recruiting, Active

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3, Pivotal Study With an Open-Label Extension Period to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-Associated Disease (MOG-AD)

Interventional
See the trial
voir la fiche
NCT04671433 - Active, Not recruiting

Phase 3 Randomized, Controlled Study of AAV5-hRKp.RPGR for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene

Interventional
See the trial
voir la fiche
NCT04794101 - Active, Not recruiting

Phase 3 Follow-up Study of AAV5-hRKp.RPGR for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene

Interventional
See the trial
voir la fiche
NCT04127006 - Active, Not recruiting

Rate of Progression in EYS Related Retinal Degeneration (Pro-EYS).

Observational
See the trial
voir la fiche
NCT03913143 - Active, Not recruiting

A double-masked, randomized, controlled, multiple-dose study to evaluate the efficacy, safety, tolerability and systemic exposure of QR-110 in Subjects with Leber’s Congenital Amaurosis (LCA) due to c.2991+1655A>G mutation (p.Cys998X) in the CEP290 gene (Illuminate).

Interventional
See the trial
voir la fiche
NCT03293524 - Active, Not recruiting

Efficacy & Safety Study of Bilateral Intravitreal Injection of GS010 in LHON Subjects Due to the ND4 Mutation for up to 1 Year (REFLECT).

Interventional
See the trial
voir la fiche
NCT03140969 - Completed

Study to Evaluate QR-110 in Subjects With Leber’s Congenital Amaurosis (LCA) Due to the c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene.

Interventional
See the trial
voir la fiche
NCT03146078 - Active, Not recruiting

Rate of Progression in USH2A Related Retinal Degeneration

Observational
See the trial
voir la fiche
NCT02796274 - Completed

Historical Case Record Survey of Visual Acuity Data From Patients With Leber’s Hereditary Optic Neuropathy (LHON).

Interventional
See the trial
voir la fiche
NCT02544217 - Completed

A Phase I, Randomized, Double Blind, Placebo-controlled, Dose-escalating Clinical Trial With KH176.

Interventional
See the trial
voir la fiche
NCT04295304 - Terminated

Safety and Performance Evaluation of the NR600 System in Subjects With End-stage Inherited Outer Retinal Degenerative Diseases

Interventional
See the trial
voir la fiche
NCT05811351 - Recruiting, Active

A Phase 2b, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

Interventional
See the trial
voir la fiche
NCT05436665 - Recruiting, Active

The Belgian Endothelial Surgical Transplant of the Cornea:Clinical and Patient-reported Outcomes of Descemet Stripping Automated Endothelial Keratoplasty(DSAEK) Versus Descemet Membrane Endothelial Keratoplasty(DMEK)

Interventional
See the trial
voir la fiche
NCT06294613 - Recruiting, Active

A Prospective, Open-label, Single-center, Study of the ACUSURGICAL Luca System for Treatment of Vitreoretinal Diseases

Interventional
See the trial
voir la fiche
NCT00481546 - Active, Not recruiting

Phase I Trial of Gene Vector to Patients with Retinal Disease due toRPE65 mutations

Interventional
See the trial
voir la fiche
NCT03992417 - Active, Not recruiting

A Prospective Observational Study of Patients Receiving Dupixent® for Atopic Dermatitis

Observational
See the trial
voir la fiche